← FDA DRUG APPROVALS

FDA BLA · BLA761445

SARCLISA ESCENA

isatuximab-irfc

Sponsor: SANOFI-AVENTIS U.S. LLC

APPLICATION
BLA761445
TYPE
BLA
ORIGINAL APPROVAL
2026-07-09
LATEST ACTION
2026-07-09
ROUTE
SUBCUTANEOUS, SINGLE-DOSE
DOSAGE FORM
VIAL
MARKETING STATUS
Prescription

Products

SARCLISA ESCENAPrescription
ISATUXIMAB-IRFC 1400MG/10ML (140MG/ML) · VIAL · SINGLE-DOSE

Approval history

2026-07-09Type 3 - New Dosage Form · Original · standardLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Biologics industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →